ES2088971T3 - Amilina para el tratamiento de trastornos oseos. - Google Patents

Amilina para el tratamiento de trastornos oseos.

Info

Publication number
ES2088971T3
ES2088971T3 ES90307471T ES90307471T ES2088971T3 ES 2088971 T3 ES2088971 T3 ES 2088971T3 ES 90307471 T ES90307471 T ES 90307471T ES 90307471 T ES90307471 T ES 90307471T ES 2088971 T3 ES2088971 T3 ES 2088971T3
Authority
ES
Spain
Prior art keywords
amylin
bone
treatment
disorders
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90307471T
Other languages
English (en)
Inventor
Iain Macintyre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2088971T3 publication Critical patent/ES2088971T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USO DE AMILINA O VARIANTES DE AMILINA, ASI COMO AGONISTAS DE AMILINA, PARA EL TRATAMIENTO DE DESORDENES OSEOS, EN PARTICULAR OSTEOPOROSIS. LA ENFERMEDAD DE PAGET Y LOS DEPOSITOS MALIGNOS EN LOS HUESOS, PERDIDA OSEA DE MALIGNIDAD, DESORDENES ENDOCRINOS, ARTRITIS AUTOINMUNE O INMOVILIDAD O DESUSO, Y EN OTRAS CONDICIONES EN LAS QUE RESULTA BENEFICIOSO UN EFECTO HIPOCALCAEMICO. SE PROPORCIONAN LOS FRAGMENTOS DE PEPTIDOS FUNCIONALES DE AMILINA, O UNA VARIANTE DE AMILINA O FRAGMENTO DE AMILINA, ASI COMO UNA AMILINA SOLUBLE, FRAGMENTOS DE AMILINA O SUS VARIANTES, O UN PRODUCTO LIOFILIZADO O UNA FORMULACION ORAL PARA SU USO SOLO O EN COMBINACION CON OTROS AGENTES, INCLUIDA LA INSULINA (O AGENTES ESTIMULANTES DE LA INSULINA, INCLUIDOS PERO NO LIMITANDOSE A LAS SULFONILUREAS) Y ESTROGENOS, PARA EL TRATAMIENTO DE DESORDENES DE EQUILIBRIO OSEO O CALCICO.
ES90307471T 1989-07-08 1990-07-09 Amilina para el tratamiento de trastornos oseos. Expired - Lifetime ES2088971T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898915712A GB8915712D0 (en) 1989-07-08 1989-07-08 Medical treatment

Publications (1)

Publication Number Publication Date
ES2088971T3 true ES2088971T3 (es) 1996-10-01

Family

ID=10659773

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90307471T Expired - Lifetime ES2088971T3 (es) 1989-07-08 1990-07-09 Amilina para el tratamiento de trastornos oseos.

Country Status (12)

Country Link
EP (1) EP0408284B1 (es)
JP (1) JPH04500691A (es)
AT (1) ATE137975T1 (es)
CA (1) CA2020752C (es)
DE (1) DE69026986T2 (es)
DK (2) DK0408284T3 (es)
ES (1) ES2088971T3 (es)
GB (1) GB8915712D0 (es)
GR (1) GR3020680T3 (es)
IE (1) IE62625B1 (es)
SG (1) SG46382A1 (es)
WO (1) WO1991000710A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109604A1 (en) * 1991-05-24 1992-11-26 Timothy J. Rink Insulin and amylin containing composition for the treatment of insulin deficient mammals
ATE157010T1 (de) * 1991-05-24 1997-09-15 Amylin Pharmaceuticals Inc Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
BRPI9509411B8 (pt) 1994-10-21 2021-07-06 Nps Pharma Inc composto modulador de receptor de íon inorgânico e composição farmacêutica
ES2201300T3 (es) * 1996-05-01 2004-03-16 Nps Pharmaceuticals, Inc. Compuestos activos frente a receptores de iones inorganicos.
ATE348589T1 (de) * 1997-09-26 2007-01-15 Auckland Uniservices Ltd Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
GB8407907D0 (en) * 1984-03-27 1984-05-02 Sandoz Ltd Organic compounds
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4677132A (en) * 1986-03-12 1987-06-30 American Home Products Corporation Inhibition of bone resorption by etodolac
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
AU619579B2 (en) * 1988-07-22 1992-01-30 Ethyl Corporation Silicon compounds in bone treatment

Also Published As

Publication number Publication date
WO1991000710A1 (en) 1991-01-24
ATE137975T1 (de) 1996-06-15
DK40191D0 (da) 1991-03-07
GB8915712D0 (en) 1989-08-31
GR3020680T3 (en) 1996-10-31
JPH04500691A (ja) 1992-02-06
EP0408284B1 (en) 1996-05-15
DK40191A (da) 1991-03-07
DE69026986T2 (de) 1996-10-02
IE62625B1 (en) 1995-02-22
IE902494A1 (en) 1991-02-13
DK0408284T3 (da) 1996-06-03
CA2020752C (en) 1996-12-24
SG46382A1 (en) 1998-02-20
CA2020752A1 (en) 1992-01-10
DE69026986D1 (de) 1996-06-20
EP0408284A2 (en) 1991-01-16
EP0408284A3 (en) 1992-01-08

Similar Documents

Publication Publication Date Title
ES2088971T3 (es) Amilina para el tratamiento de trastornos oseos.
ATE111331T1 (de) Schiene zur behandlung der fraktur von colles.
ES2113635T3 (es) Aplicacion del riluzole en el tratamiento de lesiones neurologicas relacionadas con traumatismos.
IS2132B (is) Notkun á estrogeni til framleiðslu á lyfi til meðhöndlunar vegna tíðahvarfa
NO303863B1 (no) Anvendelse av benzotiofener for forhindring av bentap
GB2193102B (en) Fracture brace
EP0313295A3 (en) Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
GB8621816D0 (en) Therapeutic composition
FR2651435B1 (es)
EP0330756A3 (en) Thienotricyclics for the treatment of bronchial diseases
EP0295827A3 (en) Use of 24,25-dihydroxy-cholecalciferol in mending bone fractures
IL132354A0 (en) Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
NZ221473A (en) Octapeptide somatostatin analogue "octreotide" in nasal compositions
Chung et al. A New Classification of Polydactyly and It s Application to the Treatment
Maki et al. Follow-Up Study on Tendon Transfer for Extension Disturbance of Wrist, Thumb, and Finger
ES296580U (es) Clavo para la osteosintesis de las fracturas de huesos
ES2048080A1 (es) Clavo intramedular para la reduccion de fracturas oseas.
ES2015772A6 (es) Procedimiento e obtencion de nuevos derivados del 5-fluorouracilo, concretamente los n1-acil-sustituidos-n3-orto-toluil-5-fluorouracilo.
GR860458B (en) Orthopedic shoe sole
IT1238074B (it) Composti per il trattamento della malattia di paget,dell'ipercalcemia e dell'osteoporosi ottenuti per complessazione di una delle calcitonine con una ciclodestrina, loro preparazione e relative composizioni farmaceutiche
CS768788A1 (en) Dispersing agent for leathers' surface treatment properties improvement
ITNA910011U1 (it) Suoletta sottopiede resa poco rigida grazie all'asportazione di parte della zona plantare.
HK16592A (en) Somatostatin analogues for the treatment of breast cancer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 408284

Country of ref document: ES

FG2A Definitive protection

Ref document number: 408284

Country of ref document: ES